Description du projet
L’optimisation de l’hyperthermie comme traitement anticancéreux
L’augmentation de la température des tumeurs jusqu’à 40-44 °C, un processus appelé hyperthermie, apparaît comme un traitement anticancéreux intéressant pouvant servir à renforcer l’efficacité de la radiothérapie ou de la chimiothérapie. L’objectif principal du projet HYPERBOOST, financé par l’UE, consiste à améliorer davantage l’efficacité et la synergie de l’hyperthermie en identifiant et en appliquant des niveaux de température optimaux au bon moment avec d’autres modalités dans différents types de tumeurs. Les chercheurs étudieront les mécanismes à l’origine des effets thérapeutiques de l’hyperthermie par le biais d’une approche interdisciplinaire combinant la biologie, la physique et l’oncologie. Les connaissances et les outils pratiques obtenus ouvriront la voie à un traitement d’hyperthermie personnalisé aux résultats cliniques accrus.
Objectif
Hyperthermia (HT), heating tumors to temperatures of 40-44°C, is an oncological treatment used in combination with
radiotherapy (RT) and chemotherapy to enhance their efficacy. Clinical effectiveness of HT has been demonstrated in
randomised studies and HT is currently applied for many clinical indications, like cervical cancer and recurrent breast cancer.
Clinical results can be further improved as application of HT with well-controlled tumor temperatures and optimal timing and
sequence realising full synergy of RT+HT is challenging. Optimal HT delivery requires accurate planning, moreover
preclinical research has shown that many mechanisms are responsible for the therapeutic effect of HT, all presumably with a
different temperature-effect relationship and with different optimal timing between RT and HT. Optimisation of clinical RT+HT
treatments therefore requires a quantum leap in understanding and in clinical application.
Scientific objective of this multidisciplinary project with contributions from all sectors and disciplines (biology, physics and
oncology) is to combine training and research into the synergistic molecular mechanisms responsible for the therapeutic
effect of HT on RT with the development of a versatile and innovative planning platform which utilises biological knowledge
to achieve optimal patient-specific treatment delivery and ultimately application in a clinical registration study in a network of
European centres implementing this treatment planning software to ensure optimal treatment delivery.
This ground-breaking and multidisciplinary project with contributions from biology, physics and oncology will create a
versatile and innovative planning platform, enhance fundamental knowledge and create practical tools to achieve
personalised treatment, thereby augmenting treatment delivery and clinical results. The projects will also educate 15 highly
skilled professionals capable of addressing and solving complex oncological issues.
Champ scientifique
Programme(s)
Régime de financement
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinateur
1081 HV Amsterdam
Pays-Bas